NCT03236311 - A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 12, 2017

Primary Completion Date

July 23, 2018

Study Completion Date

July 23, 2018

Conditions

Microvascular Coronary Artery Disease

Interventions

DRUG

SAR407899

Pharmaceutical form: Capsule Route of administration: Oral

DRUG

Placebo

Pharmaceutical form: Capsule Route of administration: Oral

DRUG

Adenosine

Pharmaceutical form: Solution for injection Route of administration: Intravenous

DRUG

Regadenoson

Pharmaceutical form: Solution for injection Route of administration: Intravenous

DRUG

13N-ammonia

Pharmaceutical form: Solution for injection Route of administration: Intravenous

DRUG

82Rubidium

Pharmaceutical form: Solution for injection Route of administration: Intravenous

Trial Locations (10)

2400

Investigational Site Number 2080001, København NV

19104

Investigational Site Number 8400010, Philadelphia

21287

Investigational Site Number 8400008, Baltimore

32209

Investigational Site Number 8400001, Jacksonville

33449

Investigational Site Number 8400013, Wellington

90048

Investigational Site Number 8400003, Los Angeles

02115

Investigational Site Number 8400006, Boston

6525 GA

Investigational Site Number 5280001, Nijmegen

03722

Investigational Site Number 4100002, Seoul

221 85

Investigational Site Number 7520001, Lund